Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.85 |
| ▸ | TUBB | P07437 | 1/20 | 0.85 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.85 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.85 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.85 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.85 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.85 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.85 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.85 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.85 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.85 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.85 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.85 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.85 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.85 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indibulin SCHEMBL29355017 | 0.92 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Indibulin SCHEMBL3165856 | 0.92 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29649082 | 0.92 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23625291 | 0.91 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15908288 | 0.91 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6103193 | 0.91 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3151543 | 0.91 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3845507 | 0.91 | TUBB4A (0.76) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Hydrochloric Acid SCHEMBL4920187 | 0.90 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL23625153 | 0.88 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809279-B1 | PARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR | BAXTER INT (US) | 2013-05-29 | — | — | EP | claimed |
| EP-1218006-B1 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES COMPRISING THERAPEUTICALLY VALUABLE PROPERTIES | ZIOPHARM ONCOLOGY INC (US) | 2010-03-03 | — | — | EP | claimed |
| EP-0931063-B3 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ZIOPHARM ONCOLOGY INC (US) | 2009-04-08 | — | — | EP | claimed |
| US-7452910-B2 | Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties | ZIOPHARM ONCOLOGY, INC. (US) | 2008-11-18 | — | — | US | claimed |
| US-20080057124-A1 | Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties | ASIA MEDICA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | US | claimed |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ASTA MEDICA AKTIENGESELLSCHAFT | 2008-01-31 | — | — | US | claimed |
| EP-1809279-A1 | NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR | BAXTER INTERNATIONAL INC. (US) | 2007-07-25 | — | — | EP | claimed |
| EP-0931063-B1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | BAXTER HEALTHCARE SA (CH) | 2006-10-18 | — | — | EP | claimed |
| US-20060110462-A1 | Nanoparticulate compositions of tubulin inhibitor compounds | ZIOPHARM ONCOLOGY, INC. | 2006-05-25 | — | — | US | claimed |
| WO-2006052712-A1 | NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR | BAXTER INTERNATIONAL INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20030195360-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ASTA MEDICA AKTIENGESELLSCHAFT | 2003-10-16 | — | — | US | claimed |
| US-20030023093-A1 | United states patent office | ASTA MEDICA AKTIENGESELLSCHAFT | 2003-01-30 | — | — | US | claimed |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | ZIOPHARM ONCOLOGY, INC. | 2002-10-31 | — | — | US | claimed |
| EP-1218006-A2 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES COMPRISING THERAPEUTICALLY VALUABLE PROPERTIES | Baxter Healthcare S.A. (CH) | 2002-07-03 | — | — | EP | claimed |
| US-6232327-B1 | AND PHYSIOLOGICALLY TOLERABLE ACID ADDITION SALTS, N-OXIDES | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-05-15 | — | — | US | claimed |
| WO-2001022954-A2 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES SERVING AS ANTITUMOR AGENTS | BAXTER HEALTHCARE SA (CH) | 2001-04-05 | — | — | WO | claimed |
| EP-1071420-A1 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY | ASTA Medica Aktiengesellschaft (DE) | 2001-01-31 | — | — | EP | claimed |
| WO-1999051224-A1 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-10-14 | — | — | WO | claimed |
| EP-0931063-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA Medica Aktiengesellschaft (DE) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009946-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1998-03-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023093-A1 | United states patent office | IDO1, IDO2, TDO2 | TUBB4A 2404/4885TUBB 1691/4885TUBA3C 2087/4885 |
| US-20080057124-A1 | Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties | IDO2, IDO1, GLS | TUBB4A 1493/4885TUBB 1122/4885TUBA3C 742/4885 |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | IDO1, IDO2, TDO2 | TUBB4A 2279/4885TUBB 1817/4885TUBA3C 1860/4885 |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | IDO1, IDO2, INMT | TUBB4A 3117/4885TUBB 3238/4885TUBA3C 1665/4885 |
| US-20060110462-A1 | Nanoparticulate compositions of tubulin inhibitor compounds | TUBB, TUBB1, TUBB6 | TUBB4A 11/4885TUBB 1/4885TUBA3C 15/4885 |
| US-20030195360-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | IDO1, IDO2, TDO2 | TUBB4A 2359/4885TUBB 1851/4885TUBA3C 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.